

Chapter 220

Topical and Intralesional Cytotoxic Agents

Aieska De Souza, Megan M. Moore,
& Bruce E. Strober

REFERENCES

1. Askew DA et al: Effectiveness of 5-fluorouracil treatment for actinic keratosis—A systematic review of randomized controlled trials. *Int J Dermatol* **48**:453-463, 2009
2. Jury C et al: A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment. *Br J Dermatol* **153**:808, 2005 [PMID: 16181465]
3. Jorizzo J et al: Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. *Cutis* **70**:335, 2002 [PMID: 12502122]
4. Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. *J Dermatolog Treat* **20**:328-335, 2009
5. Oh C et al: Intralesional fluorouracil injection in infantile digital fibromatosis. *Arch Dermatol* **141**:549, 2005 [PMID: 15897374]
6. Kontochristopoulos G et al: Intralesional 5-fluorouracil in the treatment of keloids: an open clinical and histopathologic study. *J Am Acad Dermatol* **52**:474, 2005 [PMID: 15761426]
7. Nanda S, Reddy B: Intralesional 5-fluorouracil as a treatment modality of keloids. *Dermatol Surg* **30**:54, 2004 [PMID: 14692928]
8. Levy S, Furst K, Chern W: A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. *Clin Ther* **23**:908, 2001 [PMID: 11440290]
9. Kim Y: Management with topical nitrogen mustard in mycosis fungoides. *Dermatol Ther* **16**:288, 2003 [PMID: 14686971]
10. Ritschel WA et al: Stability of the nitrogen mustard mechlorethamine in novel formulations for dermatological use. *Int J Pharm* **362**:67-73, 2008
11. Whittaker SJ, Foss FM: Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. *Cancer Treat Rev* **33**:146-160, 2007
12. Handler R, Medansky R: Treatment of psoriasis with topical nitrogen mustard. *Int J Dermatol* **18**:758, 1979 [PMID: 511440]
13. Arrazola J et al: Treatment of alopecia areata with topical nitrogen mustard. *Int J Dermatol* **24**:608, 1985 [PMID: 4066107]
14. Berman B, Chang D, Shupack J: Histiocytosis X: Treatment with topical nitrogen mustard. *J Am Acad Dermatol* **3**:23, 1980 [PMID: 6967494]
15. de Quatrebarbes J et al: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: A prospective study. *Arch Dermatol* **141**:1117, 2005
16. Zackheim H, Epstein EH, Crain W: Topical carmustine (BCNU) for cutaneous T cell lymphoma: A 15-year experience in 143 patients. *J Am Acad Dermatol* **22**:802, 1990 [PMID: 2347966]
17. Ramírez-Amador V et al: Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. *Oral Oncol* **38**:460-467, 2002
18. Tanaka H et al: Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. *Cancer Res* **69**:6987-6994, 2009
19. Saitta P, Krishnamurthy K, Brown LH: Bleomycin in dermatology: A review of intralesional applications. *Dermatol Surg* **34**:1299-1313, 2008
20. Boudreaux A et al: Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection. *J Am Acad Dermatol* **28**:61, 1993 [PMID: 8381146]
21. Munn S et al: A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. *Br J Dermatol* **135**:969, 1996 [PMID: 8977721]

22. Dhar SB et al: Intralesional bleomycin in the treatment of cutaneous warts: A randomized clinical trial comparing it with cryotherapy. *Indian J Dermatol Venereol Leprol* **75**:262-267, 2009
23. Amer M et al: Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant warts. *J Am Acad Dermatol* **18**:1313, 1988 [PMID: 2454980]
24. Shelley W, Shelley E: Intralesional bleomycin sulfate therapy for warts. A novel bifurcated needle puncture technique. *Arch Dermatol* **127**:234, 1991 [PMID: 1703756]
25. Pollock B, Sheehan-Dare R: Pulsed dye laser and intralesional bleomycin for treatment of resistant viral hand warts. *Lasers Surg Med* **30**:135, 2002 [PMID: 11870793]
26. Saray Y, Gulec A: Treatment of keloids and hypertrophic scars with dermojet injections of bleomycin: a preliminary study. *Int J Dermatol* **44**:777, 2005 [PMID: 16135153]
27. Epstein J et al: Topical bleomycin for the treatment of dysplastic oral leukoplakia. *Cancer* **83**:629, 1998 [PMID: 9708924]
28. Watring W et al: Treatment of recurrent Paget's disease of the vulva with topical bleomycin. *Cancer* **41**:10, 1978 [PMID: 75051]
29. de la Torre C, Losada A, Cruces M: Keratoacanthoma centrifugum marginatum: Treatment with intralesional bleomycin. *J Am Acad Dermatol* **37**:1010, 1997
30. Miller R: Nail dystrophy following intralesional injections of bleomycin for a periungual wart. *Arch Dermatol* **120**:963, 1984 [PMID: 6203491]
31. Epstein E: Intralesional bleomycin and Raynaud's phenomenon. *J Am Acad Dermatol* **24**:785, 1991 [PMID: 1714468]
32. Abess A, Keel D, Graham B: Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. *Arch Dermatol* **139**:337, 2003 [PMID: 12622626]
33. Chan E, Cronstein B: Molecular action of methotrexate in inflammatory diseases. *Arthritis Res* **4**:266, 2002 [PMID: 12106498]
34. Cohen PR et al: Intralesional methotrexate for keratoacanthoma of the nose. *Skinmed* **4**:393-395, 2005
35. Annest NM et al: Intralesional methotrexate treatment for keratoacanthoma tumors: A retrospective study and review of the literature. *J Am Acad Dermatol* **56**:989-993, 2007
36. Canel C et al: Podophyllotoxin. *Phytochemistry* **54**:115, 2000 [PMID: 10872202]
37. Türkmen M et al: Facial angiofibromas of tuberous sclerosis: Successful treatment with podophyllin. *J Eur Acad Dermatol Venereol* **23**:713-714, 2009
38. Longstaff E, von Krogh G: Condyloma eradication: Self-therapy with 0.15–0.5% podophyllotoxin versus 20–25% podophyllin preparations—An integrated safety assessment. *Regul Toxicol Pharmacol* **33**:117, 2001 [PMID: 11350195]
39. Lacey C et al: Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. *Sex Transm Infect* **79**:270, 2003 [PMID: 12902571]
40. Bäumer W et al: The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models. *Eur J Pharmacol* **628**(1-3):226-232, 2010; [Epub Nov 14, 2009]
41. Dumontet C et al: A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma. *Bull Cancer* **93**:E115-E118, 2006
42. Mahieu-Renard L et al: Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine. *Ann Dermatol Venereol* **132**:346, 2005 [PMID: 15886562]
43. Hartmann K et al: Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. *Br J Dermatol* **162**(1):185-190, 2010; [Epub Aug 3, 2009]
44. Leonard R et al: Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. *J Clin Oncol* **19**:4150, 2001 [PMID: 11689583]